RPRX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
RPRX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Days Inventory is also known as Days Sales of Inventory (DSI). Royalty Pharma's Average Total Inventories for the three months ended in Dec. 2023 was $0 Mil. Royalty Pharma's Cost of Goods Sold for the three months ended in Dec. 2023 was $0 Mil.
The historical rank and industry rank for Royalty Pharma's Days Inventory or its related term are showing as below:
Royalty Pharma's Days Inventory stayed the same from Dec. 2022 (0.00) to Dec. 2023 (0.00).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Royalty Pharma's Inventory-to-Revenue for the three months ended in Dec. 2023 was 0.00.
The historical data trend for Royalty Pharma's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Royalty Pharma Annual Data | ||||||||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Days Inventory | Get a 7-Day Free Trial | - | - | - | - | - |
Royalty Pharma Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Days Inventory | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Royalty Pharma's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Royalty Pharma's Days Inventory distribution charts can be found below:
* The bar in red indicates where Royalty Pharma's Days Inventory falls into.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Royalty Pharma's Days Inventory for the fiscal year that ended in Dec. 2023 is calculated as
Days Inventory (A: Dec. 2023 ) | |||||||||
= | Average Total Inventories | / | Cost of Goods Sold | * | Days in Period | ||||
= | ( (Total Inventories (A: Dec. 2022 ) | + | Total Inventories (A: Dec. 2023 )) | / | count ) | / | Cost of Goods Sold (A: Dec. 2023 ) | * | Days in Period |
= | ( (0 | + | 0) | / | 1 ) | / | 0 | * | 365 |
= | 0 | / | 0 | * | 365 | ||||
= | N/A |
Royalty Pharma's Days Inventory for the quarter that ended in Dec. 2023 is calculated as:
Days Inventory (Q: Dec. 2023 ) | |||||||||
= | Average Total Inventories | / | Cost of Goods Sold | * | Days in Period | ||||
= | ( (Total Inventories (Q: Sep. 2023 ) | + | Total Inventories (Q: Dec. 2023 )) | / | count ) | / | Cost of Goods Sold (Q: Dec. 2023 ) | * | Days in Period |
= | ( (0 | + | 0) | / | 1 ) | / | 0 | * | 365 / 4 |
= | 0 | / | 0 | * | 365 / 4 | ||||
= | N/A |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Royalty Pharma (NAS:RPRX) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Royalty Pharma's Inventory Turnover for the three months ended in Dec. 2023 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Royalty Pharma's Inventory to Revenue for the three months ended in Dec. 2023 is calculated as
Inventory-to-Revenue | = | Average Total Inventories | / | Revenue |
= | 0 | / | 596.068 | |
= | 0.00 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Thank you for viewing the detailed overview of Royalty Pharma's Days Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.
Rory B Riggs | director | 65 RAILROAD AVE, RIDGEFIELD NJ 07657 |
Avara Management Ltd | 10 percent owner | C/O GISEV FAMILY OFFICE SA, CONTRADA DI SASSELLO 2, LUGANO V8 6900 |
Terrance P. Coyne | officer: EVP & CFO | C/O ROYALTY PHARMA PLC, 110 EAST 59TH STREET, NEW YORK NY 10022 |
Pablo G. Legorreta | director, officer: CEO, Chairman of the Board | 110 E 59TH STREET, SUITE 3300, NEW YORK NY 10022 |
George W. Lloyd | officer: EVP, Investments & GC | C/O ROYALTY PHARMA PLC, 110 EAST 59TH STREET, NEW YORK NY 10022 |
Marshall Urist | officer: EVP, Research & Investments | C/O ROYALTY PHARMA PLC, 110 EAST 59TH STREET, NEW YORK NY 10022 |
Mario Germano Giuliani | director, 10 percent owner | C/O GISEV FAMILY OFFICE SA, CONTRADA DI SASSELLO 2, LUGANO V8 6900 |
James F. Reddoch | officer: EVP, Research & Investments | C/O ROYALTY PHARMA PLC, 110 EAST 59TH STREET, NEW YORK NY 10022 |
Nogra Group Sicaf Sif Gg Strategic | 10 percent owner | C/O NOGRA GROUP SICAF-SIF S.A., 18 AVENUE DE LA PORTE NEUVE, LUXEMBOURG N4 L-2227 |
Nogra Group Sicaf - Sif S.a. | 10 percent owner | 18 AVENUE DE LA PORTE NEUVE, LUXEMBOURG N4 L-2227 |
Catherine M. Engelbert | director | 110 NORTH CARPENTER STREET, CHICAGO IL 60607 |
Errol B Desouza | director | 215 COLLEGE ROAD, PARAMUS NJ 07652 |
Henry A Fernandez | director | MSCI INC., 88 PINE STREET, NEW YORK NY 10005 |
Gregory Norden | director | 16640 CHESTERFIELD GROVE DRIVE, SUITE 200, CHESTERFIELD MO 63005 |
Ted W Love | director | C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080 |
From GuruFocus
By Business Wire • 08-24-2023
By Marketwired • 08-24-2023
By Marketwired • 07-17-2023
By Marketwired • 10-19-2023
By GuruFocus Research GuruFocus Editor • 05-18-2023
By sperokesalga sperokesalga • 02-09-2023
By GuruFocus Research GuruFocus Editor • 02-20-2023
By sperokesalga sperokesalga • 06-07-2023
By sperokesalga sperokesalga • 04-13-2023
By GuruFocus Research GuruFocus Editor • 01-28-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.